MX9403386A - Pirrolidin-3-il-alquilpiperidinas sustituidas. - Google Patents
Pirrolidin-3-il-alquilpiperidinas sustituidas.Info
- Publication number
- MX9403386A MX9403386A MX9403386A MX9403386A MX9403386A MX 9403386 A MX9403386 A MX 9403386A MX 9403386 A MX9403386 A MX 9403386A MX 9403386 A MX9403386 A MX 9403386A MX 9403386 A MX9403386 A MX 9403386A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted
- alquilpiperidinas
- pirrolidin
- compounds
- present
- Prior art date
Links
- 230000008485 antagonism Effects 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 101800003906 Substance P Proteins 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5860693A | 1993-05-06 | 1993-05-06 | |
| US21848394A | 1994-03-28 | 1994-03-28 | |
| US22537194A | 1994-04-19 | 1994-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9403386A true MX9403386A (es) | 1995-01-31 |
Family
ID=27369482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9403386A MX9403386A (es) | 1993-05-06 | 1994-05-06 | Pirrolidin-3-il-alquilpiperidinas sustituidas. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0696280B1 (Direct) |
| JP (1) | JP3424174B2 (Direct) |
| CN (1) | CN1081635C (Direct) |
| AT (1) | ATE158580T1 (Direct) |
| AU (1) | AU678023B2 (Direct) |
| CA (1) | CA2160462C (Direct) |
| DE (1) | DE69405862T2 (Direct) |
| DK (1) | DK0696280T3 (Direct) |
| ES (1) | ES2110761T3 (Direct) |
| FI (1) | FI113047B (Direct) |
| GR (1) | GR3025475T3 (Direct) |
| HU (1) | HU224496B1 (Direct) |
| IL (1) | IL109496A (Direct) |
| MX (1) | MX9403386A (Direct) |
| NO (1) | NO309144B1 (Direct) |
| NZ (1) | NZ267209A (Direct) |
| TW (1) | TW281675B (Direct) |
| WO (1) | WO1994026735A1 (Direct) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2717802B1 (fr) * | 1994-03-25 | 1996-06-21 | Sanofi Sa | Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| HU221434B (en) | 1994-08-25 | 2002-10-28 | Merrell Pharma Inc | Substituted piperidines, pharmaceutical compositions containing them and their use |
| EP0714891A1 (en) * | 1994-11-22 | 1996-06-05 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
| FR2728165A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
| FR2728169A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| HUP9702149A3 (en) * | 1995-03-15 | 1999-07-28 | Aventis Pharmaceuticals Inc Br | Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds |
| ATE277021T1 (de) * | 1995-04-13 | 2004-10-15 | Aventis Pharma Inc | Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung |
| US5661163A (en) | 1995-06-07 | 1997-08-26 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| FR2738245B1 (fr) * | 1995-08-28 | 1997-11-21 | Sanofi Sa | Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant |
| FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
| WO1997013514A1 (en) * | 1995-10-10 | 1997-04-17 | Pfizer Inc. | Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy |
| US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
| US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
| WO1997022604A1 (en) * | 1995-12-20 | 1997-06-26 | Hoechst Marion Roussel, Inc. | Novel substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| GB9600235D0 (en) * | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
| US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
| US5998439A (en) * | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
| US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
| US5977139A (en) * | 1996-12-15 | 1999-11-02 | Hoechst Marion Roussel, Inc. | Carboxysubstituted cyclic carboxamide derivatives |
| IL130222A0 (en) * | 1996-12-19 | 2000-06-01 | Hoechst Marion Roussel Inc | Novel carboxy substituted cyclic carboxamide derivatives |
| US5861417A (en) * | 1996-12-19 | 1999-01-19 | Hoechst Marion Roussel, Inc. | Heterocyclic substituted pyrrolidine amide derivatives |
| DE69710921T2 (de) * | 1996-12-19 | 2002-09-19 | Aventis Pharmaceuticals Inc., Bridgewater | Heterocyclische substituierte pyrrolidinamid-derivate |
| NZ513904A (en) | 1997-05-30 | 2001-09-28 | Sankyo Co | Salts of optically active sulfoxide derivative |
| ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
| RU2309953C2 (ru) | 1999-11-03 | 2007-11-10 | Эймр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| CN100430401C (zh) | 2000-07-11 | 2008-11-05 | Amr科技公司 | 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途 |
| WO2004055016A1 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Pyrrolidine and azetidine compounds as ccr5 antagonists |
| TW200524868A (en) | 2003-07-31 | 2005-08-01 | Zeria Pharm Co Ltd | Benzylamine derivatives |
| US20070078120A1 (en) * | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
| GB0412865D0 (en) * | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| CA2573271C (en) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| CA2584241A1 (en) * | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | Cgrp receptor antagonists |
| CA2601709C (en) | 2005-03-22 | 2017-02-14 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| NZ565111A (en) | 2005-07-15 | 2011-10-28 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2007011878A2 (en) | 2005-07-19 | 2007-01-25 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| JP2011515343A (ja) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | チロシンキナーゼ阻害薬 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| EP2429296B1 (en) | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| AU2010307198B9 (en) | 2009-10-14 | 2014-02-13 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| WO2011137012A1 (en) | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| DK2606134T3 (da) | 2010-08-17 | 2019-07-22 | Sirna Therapeutics Inc | RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| ES2663009T3 (es) | 2010-10-29 | 2018-04-10 | Sirna Therapeutics, Inc. | Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| CA2831730A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| NZ724718A (en) | 2014-03-28 | 2023-04-28 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
| EP3317279B1 (en) * | 2015-07-03 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Triaza-spirodecanones as ddr1 inhibitors |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| BR112020005107A2 (pt) | 2017-09-15 | 2020-11-03 | Azevan Pharmaceuticals, Inc. | composições e métodos para o tratamento de lesão cerebral |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| JP7446282B2 (ja) | 2018-08-07 | 2024-03-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｒｍｔ５阻害剤 |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
-
1994
- 1994-04-22 ES ES94917898T patent/ES2110761T3/es not_active Expired - Lifetime
- 1994-04-22 CN CN94192362A patent/CN1081635C/zh not_active Expired - Fee Related
- 1994-04-22 EP EP94917898A patent/EP0696280B1/en not_active Expired - Lifetime
- 1994-04-22 DE DE69405862T patent/DE69405862T2/de not_active Expired - Lifetime
- 1994-04-22 JP JP52545394A patent/JP3424174B2/ja not_active Expired - Fee Related
- 1994-04-22 WO PCT/US1994/004498 patent/WO1994026735A1/en not_active Ceased
- 1994-04-22 AU AU69426/94A patent/AU678023B2/en not_active Ceased
- 1994-04-22 AT AT94917898T patent/ATE158580T1/de not_active IP Right Cessation
- 1994-04-22 HU HU9503153A patent/HU224496B1/hu not_active IP Right Cessation
- 1994-04-22 DK DK94917898.2T patent/DK0696280T3/da active
- 1994-04-22 NZ NZ267209A patent/NZ267209A/en unknown
- 1994-04-22 CA CA002160462A patent/CA2160462C/en not_active Expired - Fee Related
- 1994-04-26 TW TW083103768A patent/TW281675B/zh active
- 1994-05-02 IL IL10949694A patent/IL109496A/xx not_active IP Right Cessation
- 1994-05-06 MX MX9403386A patent/MX9403386A/es unknown
-
1995
- 1995-11-02 FI FI955258A patent/FI113047B/fi not_active IP Right Cessation
- 1995-11-03 NO NO954400A patent/NO309144B1/no not_active IP Right Cessation
-
1997
- 1997-11-26 GR GR970403124T patent/GR3025475T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69405862D1 (de) | 1997-10-30 |
| IL109496A0 (en) | 1994-08-26 |
| JPH09500361A (ja) | 1997-01-14 |
| ATE158580T1 (de) | 1997-10-15 |
| GR3025475T3 (en) | 1998-02-27 |
| CA2160462A1 (en) | 1994-11-24 |
| CA2160462C (en) | 1998-12-15 |
| HUT74085A (en) | 1996-11-28 |
| WO1994026735A1 (en) | 1994-11-24 |
| ES2110761T3 (es) | 1998-02-16 |
| DE69405862T2 (de) | 1998-01-15 |
| IL109496A (en) | 2000-07-26 |
| JP3424174B2 (ja) | 2003-07-07 |
| HU224496B1 (hu) | 2005-10-28 |
| FI113047B (fi) | 2004-02-27 |
| EP0696280A1 (en) | 1996-02-14 |
| CN1081635C (zh) | 2002-03-27 |
| AU678023B2 (en) | 1997-05-15 |
| FI955258A0 (fi) | 1995-11-02 |
| TW281675B (Direct) | 1996-07-21 |
| DK0696280T3 (da) | 1998-01-12 |
| EP0696280B1 (en) | 1997-09-24 |
| HU9503153D0 (en) | 1996-01-29 |
| FI955258L (fi) | 1995-11-30 |
| NO954400D0 (no) | 1995-11-03 |
| AU6942694A (en) | 1994-12-12 |
| NO954400L (no) | 1996-01-08 |
| NZ267209A (en) | 1997-09-22 |
| CN1124961A (zh) | 1996-06-19 |
| NO309144B1 (no) | 2000-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9403386A (es) | Pirrolidin-3-il-alquilpiperidinas sustituidas. | |
| MX9301348A (es) | Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende. | |
| AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
| AR002289A1 (es) | Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias. | |
| MX9301129A (es) | Nuevas ciclosporinas y composiciones farmaceuticas que las contienen. | |
| MX9301929A (es) | Derivados de pirimidina y procedimientos para su preparacion. | |
| MX9301847A (es) | Aminas biciclicas-heterociclicas farmaceuticamente activas | |
| ES2150567T3 (es) | Antagonistas del factor de liberacion de la corticotropina. | |
| MX9207494A (es) | 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| ES2036593T3 (es) | Composiciones que utilizan medicamentos antiinflamatorios no esteroidales encapsulados en liposomas. | |
| MX9300407A (es) | Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion. | |
| MX9303670A (es) | Derivados de biciclooctano y bicicloheptano, meto do para su preparacion y composiciones farmaceuticas que los contienen. | |
| MX9303123A (es) | Ciclopentano-y-penteno-beta-aminoacidos, procedimiento para su preparacion y medicamentos que los contienen. | |
| MX9300399A (es) | Derivados heterotriciclicos. | |
| ES2171743T3 (es) | Derivados de amidinas e isotioureas como inhibidores de la enzima sintasa de oxido nitrico. | |
| MX9300423A (es) | Derivados heterociclicos. | |
| ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. | |
| ES2164283T3 (es) | Indanilidinacetilguanidinas sustituidas como inhibidores del intercambio de na+/h+, procedimiento para su preparacion, su uso como medicamentos o agentes de diagnostico y medicamentos que las contienen. | |
| MX9300406A (es) | Derivados azabiciclicos procedimientos para su preparacion y composiciones que los contienen. | |
| MX9205236A (es) | Amino-propanos sustituidos, procedimientos para su preparacion y su utilizacion. | |
| MX9400072A (es) | Agentes antiinflamatorios derivados de difluoropentapeptido. | |
| AR001352A1 (es) | Bencenofulfonifureas y bencenosulfoniltioureas sustituidas, procedimiento para sus preparaciones, sus usos para producir preprarados farmaceuticos y los medicamentos que los contienen. | |
| ES2158309T3 (es) | Fenilamidinas sustituidas, medicamentos que contienen a estos compuestos y procedimiento para su preparacion. | |
| ES2124280T3 (es) | O-fenilendiaminas que contienen grupos fluoralquil(eno) y su empleo como compuestos intermedios en la sintesis de benzimidazoles. | |
| ES2147825T3 (es) | Derivados tetraciclicos de la 1,4-oxazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |